NeuroOne to Report Fiscal Q2 2026 Financial Results on May 12, Highlights Minimally Invasive Neurological Tech
NeuroOne Medical Technologies will announce its fiscal second quarter 2026 financial results on May 12, 2026, with a focus on its FDA-cleared electrode and ablation systems that aim to reduce hospitalizations and improve outcomes for neurological disorders.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on transforming surgical diagnosis and treatment of neurological disorders, announced that it will release financial results for its fiscal second quarter ended March 31, 2026, before market open on Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern time that day to discuss the results, provide a corporate update, and answer questions from participants.
The company, based in Eden Prairie, Minnesota, markets a minimally invasive and high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions are designed to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions.
NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs, indicating a broader pipeline beyond its current cleared products. The company’s focus on minimally invasive technologies aligns with broader trends in healthcare toward less invasive procedures that can shorten recovery times and reduce healthcare costs.
Investors and analysts will be watching the upcoming earnings call for updates on revenue growth, adoption of NeuroOne’s products, and progress in its R&D pipeline. The call will be accessible via a webcast at this link, with dial-in numbers for the U.S. (888-506-0062) and international (973-528-0011) participants using access code 224785. A replay will be available through May 26, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) with passcode 53948.
The announcement comes as NeuroOne continues to navigate the competitive landscape of neurological medical devices. The company’s ability to demonstrate clinical and economic value will be key to its long-term success. With a portfolio of FDA-cleared products and ongoing R&D, NeuroOne is positioned to address unmet needs in neurosurgery, potentially benefiting patients and healthcare systems alike. The earnings report will provide a clearer picture of the company’s financial health and strategic direction.